Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 2,692 shares, a decline of 55.8% from the April 15th total of 6,089 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 4,283 shares, the days-to-cover ratio is currently 0.6 days.

Apollomics Stock Up 3.0%

Shares of NASDAQ APLM traded up $0.41 during mid-day trading on Friday, reaching $14.01. The company had a trading volume of 12,028 shares, compared to its average volume of 4,589. Apollomics has a one year low of $3.66 and a one year high of $42.12. The business’s 50-day simple moving average is $16.17 and its 200 day simple moving average is $17.52.

Analyst Ratings Changes

APLM has been the topic of a number of recent analyst reports. Wall Street Zen raised Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. 19.13% of the stock is owned by institutional investors.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.